Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects

This publication has 12 references indexed in Scilit:

• Pneumococcal pneumonia in the UK—how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)
  Vaccine, 2005
• Cost-effectiveness studies of pneumococcal conjugate vaccines
  Expert Review of Vaccines, 2004
• The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine
  Vaccine, 2003
• Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
  New England Journal of Medicine, 2003
• Cost Effectiveness of Pneumococcal Vaccination for Infants and Children with the Conjugate Vaccine PnC-7 in Germany
  PharmacoEconomics, 2003
• Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children
  The Pediatric Infectious Disease Journal, 2002
• The cost-effectiveness of routine childhood varicella vaccination in Germany
  Vaccine, 2002
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
  The Pediatric Infectious Disease Journal, 2002
• Invasive pneumococcal disease in England and Wales: what is the true burden and what is the potential for prevention using 7 valent pneumococcal conjugate vaccine?
  Archives of Disease in Childhood, 2002
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  The Pediatric Infectious Disease Journal, 2000